TL;DR
Get your next haul delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Novo Nordisk reported that it repurchased 36,604,179 B shares for DKK 10.25 billion from February 4 through October 2, 2026, under its broader share repurchase programme. The latest disclosed transactions were 245,000 shares on each of five trading days from September 28 to October 2, bringing the May programme’s total to 21.845 million shares.
Novo Nordisk said it repurchased 36,604,179 B shares for a total transaction value of DKK 10,247,270,869 between February 4 and October 2, 2026, as part of its share repurchase programme. In an October 5 company announcement, the Danish drugmaker also reported five days of additional purchases and said it held treasury shares equal to 1.1% of its share capital.
The latest transactions covered September 28 through October 2. Novo Nordisk reported buying 245,000 B shares on each of the five trading days, for a total of 1,225,000 shares. The average purchase prices were DKK 253.30 on September 28, DKK 252.74 on September 29, DKK 250.50 on September 30, DKK 249.50 on October 1, and DKK 248.77 on October 2. The company gave the combined transaction value for these purchases as DKK 307,428,837.
Those transactions bring the total under the programme launched on May 6, 2026, to 21,845,000 B shares, with a reported transaction value of DKK 6,447,270,879. Novo Nordisk said that particular programme permits repurchases of up to DKK 11,200,000,010.45 from May 6, 2026, through February 1, 2027.
The May programme is part of a broader plan to repurchase up to DKK 15 billion over a 12-month period beginning February 4, 2026. As of October 2, the company reported an average price of DKK 279.95 per B share for all purchases since that start date. The announcement says transaction-level details are published on Novo Nordisk’s website.
How the Buybacks Fit the DKK 15 Billion Plan
The announcement provides investors with an updated account of how much of Novo Nordisk’s announced repurchase plan has been carried out. The DKK 10.25 billion cumulative value reported through October 2 is measured against the company’s stated ceiling of DKK 15 billion for the 12-month plan. The company did not describe the purchases as a change in its outlook or explain the purpose of the buyback beyond setting out the programme and its limits.
Repurchases reduce the number of shares held outside the company when the bought shares are retained as treasury shares or otherwise dealt with under applicable rules. Novo Nordisk reported that it owned 50,644,876 B shares as treasury shares after the transactions described, equal to 1.1% of its share capital. The announcement does not quantify any effect on earnings per share, the share price, or shareholder returns, so those effects should not be inferred from the purchase figures alone.
For shareholders, the release offers a time-stamped record of the company’s activity and remaining stated capacity, rather than a forecast of future purchases. The weekly figures also show the prices paid on the specified dates, while the wider total reflects purchases made since February 4 and therefore covers a longer period.
As an affiliate, we earn on qualifying purchases.
Two Linked Repurchase Periods
Novo Nordisk said the overall programme began on February 4, 2026 and is intended to run for 12 months, with repurchases of up to DKK 15 billion. The separate programme described in the announcement began on May 6 and is scheduled to run through February 1, 2027, with a stated maximum of DKK 11,200,000,010.45. The company presents the May initiative as part of the larger plan, not as an additional DKK 11.2 billion on top of the DKK 15 billion ceiling.
The purchases were reported under European market-abuse safe-harbour rules cited by the company: Article 5 of Regulation No. 596/2014 and Commission Delegated Regulation (EU) 2016/1052. Novo Nordisk’s B shares trade on Nasdaq Copenhagen under the symbol Novo-B, and its American depositary receipts trade on the New York Stock Exchange under NVO. The announcement is Company Announcement No. 60/2026.
“Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026.”
— Novo Nordisk
As an affiliate, we earn on qualifying purchases.
The release does not give a schedule for purchases after October 2 or say whether Novo Nordisk will buy shares on every trading day through the programme’s end date. The stated amounts are maximums, not commitments to spend the full DKK 15 billion or the full amount authorized under the May programme.
The announcement also does not specify what Novo Nordisk plans to do with the treasury shares over the longer term, or provide a forecast of the buyback’s effect on the share price, per-share financial measures, or capital allocation. Those questions are not answered by the transaction table. The company’s reported totals and limits describe activity and programme terms as of the dates stated.
treasury shares management software
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Programme Runs Through February 2027
The May 6 programme is scheduled to continue through February 1, 2027, while the broader repurchase plan covers the 12-month period that began February 4, 2026. Novo Nordisk may issue further transaction updates as purchases are made; the company says transaction details are available on its website. The next material update will be the company’s reported purchases and cumulative totals for a later period, if and when disclosed.
investment portfolio management books
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
The company reported purchases of 245,000 B shares on each of five trading days, totaling 1,225,000 shares for the period.
How much has Novo Nordisk spent on buybacks since February 4, 2026?
As of October 2, Novo Nordisk reported repurchasing 36,604,179 B shares at an average price of DKK 279.95 per share, for a transaction value of DKK 10,247,270,869.
What is the limit for the overall repurchase plan?
Novo Nordisk says it expects to repurchase B shares for up to DKK 15 billion over a 12-month period beginning February 4, 2026. The amount is a ceiling, not a statement that the full sum will be spent.
How many treasury shares does Novo Nordisk report holding?
After the transactions in the announcement, the company reported 50,644,876 B shares as treasury shares, equal to 1.1% of its share capital.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
